[exclusive] 2017 year end inventory: Top 35 "major events" in the pharmaceutical industry

On October 18, 2017, general secretary Xi Jinping shouted at the Great Hall of the people that China entered a new era Under the background of the new era, new pattern, new atmosphere, and heavy news have emerged frequently The pharmaceutical industry has several top news that shake the whole nation's people every month At the end of this year, the author divides this year's news in the pharmaceutical industry into six categories: politics, finance, giants, academics, new drugs and anecdotes, and combs out several "big events" worth remembering in each category, so that friends can enjoy the events in the pharmaceutical industry at a time 1、 Giant strong layout No.1: Wanda rushed into the medical circle and invested 144 billion yuan! On August 2, Wanda Group newly established Wanda big health industry group Co., Ltd (hereinafter referred to as "big health group"), and incorporated the medical business department into big health group It means that Wang Jianlin has previously announced the plan of taking medical industry as Wanda's new pillar industry Up to now, Wanda has announced a total investment of 144 billion yuan in the medical industry No.2: Alibaba health pilot "medical consortia + blockchain" Stepping into the regional health information platform on August 17, Alibaba Health announced to cooperate with Changzhou medical consortia + blockchain pilot project to apply blockchain technology to the underlying technical architecture system of Changzhou medical consortia, so as to solve the long-term problems of "information island" and data security that disturb medical institutions, This is also the first blockchain solution based on medical scenario implementation in China No.3: Dr penguin's 3 clinics landed at the same time, connecting the offline entrance and various high-quality resources In September 14th, Tencent's Internet plus medical health platform Penguin doctor said that it had landed in Beijing, Chengdu and Shenzhen City, and built Penguin clinics on its own The service covers all the common departments of internal medicine, surgery, stomatology and so on In the future, 430 thousand excellent doctors in the country, who have been linked by the Medical Association, will be integrated to sign the services of family doctors NO.4: JD has entered the pharmaceutical and health industry in a large scale In August 2017, JD started to launch the JD pharmaceutical cloud warehouse project, which covers warehousing, transportation, distribution and other aspects From procurement to distribution, JD participated in the whole process, thus ensuring the integrity and efficiency of the entire supply chain No.5: Foxconn enters the pharmaceutical industry, with a single project estimated output value of 300 million yuan On March 1, 2017, Foxconn president Gou Taiming disclosed that strategic cooperation has been reached with BGI Foxconn will mass produce some of BGI's instruments and products, and decide to place some of its ongoing system medical device projects in Shaoxing Phase I of the medical device project has completed clinical trials and will enter the final administrative approval It is expected that the output value of the project in 2018 will be Up to 300 million yuan, the output value will reach 1.8 billion yuan in 2020 2、 Domestic blank new drug no.1:10 million patients suffering from hepatitis C cure drug name: sophosphibuvir (suowati) manufacturer: Gilead sophosphibuvir of the United States was officially listed in China in November 2017, his emergence ushered in the treatment of hepatitis C without interferon Sophibuvir and its combination therapy belong to the first choice scheme recommended by the World Health Organization guidelines, ending the history of hepatitis C incurable No.2: the first melanoma targeting drug to be listed in China: verofinib (zobov) manufacturer: verofinib, a Swiss Roche pharmaceutical, was approved by the State Food and Drug Administration in March 2017 It is the first oral melanoma targeting drug to be listed in China, which means that China's melanoma treatment has entered a targeted era At present, verofinil has been officially included in the Chinese melanoma diagnosis and treatment guidelines (2017 Edition), and has become a kind of recommended drug for the treatment of brafv600 gene mutation patients No.3: the world's first cervical cancer vaccine approved in China: human papillomavirus vaccine (jiadaxiu) manufacturer: Mosa dongjiadaxiu is the world's first cervical cancer vaccine, which was officially approved by the State Food and Drug Administration in May 2017 The approval of the drug means that our female compatriots can effectively prevent cervical cancer The market scale of cervical cancer vaccine is expected to exceed 10 billion yuan, which is one of the most potential vaccines in China NO.4: effective drug name of bone marrow fibrosis tumor: lucotinib phosphate (Jieke Wei) manufacturer: Novartis Jieke Wei, Switzerland, was listed in China on August 7, 2017, which is the only targeted treatment drug for the pathogenesis of bone marrow fibrosis in China Lucotinib phosphate is a powerful Jak1 / 2 inhibitor It can down regulate the JAK-STAT signal pathway to achieve the goal of targeted therapy The approval of lucotinib phosphate is a milestone in the treatment of myelofibrosis No.5: the first innovative drug in the field of heart failure in the past 20 years: the manufacturer of sakubatravsartan sodium tablets (novinol): Novartis novinoxin is the world's first angiotensin receptor enkephalinase inhibitor (Arni), which was officially approved by the State Food and Drug Administration (CFDA) for listing in China in July 2017 The drug is a breakthrough innovative drug in the field of chronic heart failure treatment in the past two decades, which can effectively reduce the risk of cardiovascular death and heart failure hospitalization 3、 No.1: BGI went public on May 24, landing on the A-share market BGI successfully held a meeting On June 23, the IPO application was approved On July 14, Huada gene (SZ: 300676) was listed in A-share market The listing of BGI is another milestone of DNA sequencing technology It can be predicted that DNA sequencing technology will penetrate into the people's homes sooner or later and serve tens of millions of families NO.2: Mindray plans to raise 6.6 billion shares to sprint a share, and a medical equipment enterprise with a market value of 100 billion will be born soon On May 26, according to the website of the CSRC, Shenzhen Mindray biomedical electronic Co., Ltd issued a prospectus for the initial public offering The company plans to be listed on the Shenzhen Stock Exchange, with no more than 121.6 million shares to be issued, accounting for no less than 10% of the total share capital after the issuance, and with a planned capital raising of about 6.626 billion yuan No.3: Yunnan Baiyao obtained 5.6 billion strategic investment On June 6, Yunnan Baiyao announced that in order to promote mixed reform and introduce third-party investors, Jiangsu Yuyue Technology Development Co., Ltd plans to increase the capital of 5.638 billion yuan to Yunnan Baiyao Holding Co., Ltd., the controlling shareholder of the company, to realize that Yunnan SASAC, Xinhua capital and Jiangsu Yuyue are the parent companies holding 45%, 45% and 10% shares of Baiyao respectively Yunnan Baiyao, as a benchmark for the reform of state-owned enterprises in Yunnan, the mixed reform is far beyond the market expectation NO.4: the first day of listing of YaoMing biology rose by 37%, with a market value of over 32 billion! On June 13, Yaoming bio was listed in Hong Kong, with an opening price of 25 Hong Kong dollars, 21.3% higher than the bidding price of 20.6 yuan per share, up 37.14% on the first day, with a total market value of 32.039 billion Hong Kong dollars (about 27.922 billion yuan) No.5: on September 15, Lianying Medical Co., Ltd completed round a financing of 3.333 billion yuan Xue min, chairman of Lianying Medical Co., Ltd., announced that Lianying Medical Co., Ltd completed round a financing with a financing amount of 3.333 billion yuan and a post investment valuation of 33.333 billion yuan China Life Health Fund and SDIC Innovation Investment Management Co., Ltd jointly lead the investment This is by far the largest single private financing completed in China's medical equipment industry 4、 International academic trends No.1: scientists first developed human pig chimeric embryos January 26, the team of scientists at Salk Research Institute published results in the journal Cell, saying that they injected human stem cells into pig embryos, successfully cultivated human pig chimeric embryos for the first time, and developed in pigs for 3 to 4 weeks No.2: FDA officially approved the launch of Novartis car-t products 2017 is the first year of car-t on August 30, FDA officially approved the launch of Novartis car-t products for the treatment of acute lympholeukemia This is the first gene therapy drug approved by FDA The appearance of car-t brings new hope to the patients with acute lymphoblastic leukemia and large B cell tumor No.3: the anti-cancer effect of personalized cancer vaccine has passed the clinical verification On July 5, nature published two articles online, which reported for the first time that the vaccine customized according to the specific cancer mutation of individuals can successfully avoid tumor recurrence in a few patients These two papers strongly show that patients can benefit from clinical trials NO.4: Chinese scholars first obtained genetically enhanced "super" stem cells by gene editing technology On July 7, the Journal of cell research published online the joint research results of Liu Guanghui research group of Institute of Biophysics, Chinese Academy of Sciences, Tang Fuhui research group of Peking University and Qu Jing research group of Institute of zoology, Chinese Academy of Sciences It was the first time that gene editing technology was used for genetic enhancement of stem cells, thus announcing the birth of the first genetic enhanced human stem cells in the world No.5: the research results of Chinese people have been published in the top medical journal JAMA, which completely subverted the concept of osteoporosis prevention and treatment On December 26, 2017, JAMA published the long papers of the research team led by Zhao Jiaguo and Zeng xiantie of foot and ankle surgery of Tianjin hospital in the form of original works and homepage cover papers The topic is: calcium / vitamin D supplementation and community-based elderly fracture incidence This paper is the first one published in JAMA in orthopaedic field in China 5、 No.1: at the end of 2017, the word "Shenyao" occupied everyone's circle of friends, and regulatory authorities, media and medical institutions began to collectively "encircle" the "Chinese Shenyao" represented by auxiliary drugs On December 2, an article titled "selling 750 million brain cleansers a year, please let go of the Chinese elderly", pushed the eye drops sapaeus to the public opinion again The spearhead is aimed at its brainwashing marketing and delays the treatment of cataract patients CFDA also responded quickly, and immediately sent a request to saps to start clinical effectiveness test as soon as possible No.2: Wang Laoji, who can prolong his life, announced on December 5 that at Fortune International Science and technology brainstorming conference, Li Chuyuan, chairman of Guangyao group, announced that the National 863 program research results showed that drinking Wang Laoji can prolong his life by about 10% Moreover, Guangyao group also said that Dong Li's remarks were "highly recognized" by Yin ye, President of BGI, and warmly applauded by all the guests I never thought that Wang Laoji, who showed up in front of the world, had such a magical effect?! In a word, this remark soon caused the doubting netizens to fry the pot However, on the afternoon of the 6th, Yin ye, chief executive of BGI, suddenly denied three times on Weibo: no recognition, no belief, we are not No.3: on December 27, Haizheng Pharmaceutical Co., Ltd was in a bad mood for consistency evaluation, and three product regulations of famous pharmaceutical companies were shot! 》In the first article, it is mentioned that tacrolimus capsule of Haizheng pharmaceutical failed to pass the drug consistency evaluation Haizheng pharmaceutical industry reacted quickly and immediately released a notice that tacrolimus capsule has been approved by the European Union for listing Is this CFDA? I just want to say, Haizheng, you are pure men! NO.4: Chinese family doctors on December 17, a Xinhua News Agency news report "more than 500 million people in China have their own family doctors, and the coverage rate of key groups is more than 65%" became a hot news Don't see don't know, a look startled: China even has 500 million people have family doctors! So are you one of them? No.5: tianwangshi cataract in the medical field, can't see clearly, SAPS eyes drop; the heart is not easy to sleep, the crown heart patent is beneficial to peace; Hello, I'm good at him, and huirenshenbao is indispensable This year's new year's day, we don't accept gifts, but only brain platinum; rheumatic bone disease, hand and foot numbness, job's tears dehumidification, Cao Qinghua; kidney deficiency, waist acid, Hongmao wine, two drinks a day; lung tonic drugs, lung tonifying pills, four times a year